200 related articles for article (PubMed ID: 12553557)
1. Improvement of left ventricular hypertrophy and arrhythmias after lanreotide-induced GH and IGF-I decrease in acromegaly. A prospective multi-center study.
Lombardi G; Colao A; Marzullo P; Biondi B; Palmieri E; Fazio S;
J Endocrinol Invest; 2002 Dec; 25(11):971-6. PubMed ID: 12553557
[TBL] [Abstract][Full Text] [Related]
2. Cardiac effects of slow-release lanreotide, a slow-release somatostatin analog, in acromegalic patients.
Baldelli R; Ferretti E; Jaffrain-Rea ML; Iacobellis G; Minniti G; Caracciolo B; Moroni C; Cassone R; Gulino A; Tamburrano G
J Clin Endocrinol Metab; 1999 Feb; 84(2):527-32. PubMed ID: 10022411
[TBL] [Abstract][Full Text] [Related]
3. Cardiovascular effects of a single slow release lanreotide injection in patients with acromegaly and left ventricular hypertrophy.
Manelli F; Desenzani P; Boni E; Bugari G; Negrini F; Romanelli G; Grassi V; Giustina A
Pituitary; 1999 Nov; 2(3):205-10. PubMed ID: 11081155
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly: six-month report on an Italian multicenter study. Italian Multicenter Slow Release Lanreotide Study Group.
Giusti M; Gussoni G; Cuttica CM; Giordano G
J Clin Endocrinol Metab; 1996 Jun; 81(6):2089-97. PubMed ID: 8964833
[TBL] [Abstract][Full Text] [Related]
5. A comprehensive study of clinical, biochemical, radiological, vascular, cardiac, and sleep parameters in an unselected cohort of patients with acromegaly undergoing presurgical somatostatin receptor ligand therapy.
Annamalai AK; Webb A; Kandasamy N; Elkhawad M; Moir S; Khan F; Maki-Petaja K; Gayton EL; Strey CH; O'Toole S; Ariyaratnam S; Halsall DJ; Chaudhry AN; Berman L; Scoffings DJ; Antoun NM; Dutka DP; Wilkinson IB; Shneerson JM; Pickard JD; Simpson HL; Gurnell M
J Clin Endocrinol Metab; 2013 Mar; 98(3):1040-50. PubMed ID: 23393175
[TBL] [Abstract][Full Text] [Related]
6. Effects of initial therapy for five years with somatostatin analogs for acromegaly on growth hormone and insulin-like growth factor-I levels, tumor shrinkage, and cardiovascular disease: a prospective study.
Colao A; Auriemma RS; Galdiero M; Lombardi G; Pivonello R
J Clin Endocrinol Metab; 2009 Oct; 94(10):3746-56. PubMed ID: 19622615
[TBL] [Abstract][Full Text] [Related]
7. Regression of acromegalic left ventricular hypertrophy after lanreotide (a slow-release somatostatin analog).
Hradec J; Kral J; Janota T; Krsek M; Hana V; Marek J; Malik M
Am J Cardiol; 1999 May; 83(10):1506-9, A8. PubMed ID: 10335774
[TBL] [Abstract][Full Text] [Related]
8. Impact of treating acromegaly first with surgery or somatostatin analogs on cardiomyopathy.
Colao A; Pivonello R; Galderisi M; Cappabianca P; Auriemma RS; Galdiero M; Cavallo LM; Esposito F; Lombardi G
J Clin Endocrinol Metab; 2008 Jul; 93(7):2639-46. PubMed ID: 18445662
[TBL] [Abstract][Full Text] [Related]
9. One-year follow-up of patients with acromegaly treated with fixed or titrated doses of lanreotide Autogel.
Caron P; Bex M; Cullen DR; Feldt-Rasmussen U; Pico Alfonso AM; Pynka S; Racz K; Schopohl J; Tabarin A; Valimaki MJ;
Clin Endocrinol (Oxf); 2004 Jun; 60(6):734-40. PubMed ID: 15163338
[TBL] [Abstract][Full Text] [Related]
10. Impact of somatostatin analogs on the heart in acromegaly: a metaanalysis.
Maison P; Tropeano AI; Macquin-Mavier I; Giustina A; Chanson P
J Clin Endocrinol Metab; 2007 May; 92(5):1743-7. PubMed ID: 17311857
[TBL] [Abstract][Full Text] [Related]
11. Cardiovascular consequences of early-onset growth hormone excess.
Colao A; Spinelli L; Cuocolo A; Spiezia S; Pivonello R; di Somma C; Bonaduce D; Salvatore M; Lombardi G
J Clin Endocrinol Metab; 2002 Jul; 87(7):3097-104. PubMed ID: 12107207
[TBL] [Abstract][Full Text] [Related]
12. Predictors of tumor shrinkage after primary therapy with somatostatin analogs in acromegaly: a prospective study in 99 patients.
Colao A; Pivonello R; Auriemma RS; Briganti F; Galdiero M; Tortora F; Caranci F; Cirillo S; Lombardi G
J Clin Endocrinol Metab; 2006 Jun; 91(6):2112-8. PubMed ID: 16537687
[TBL] [Abstract][Full Text] [Related]
13. Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial.
Gadelha MR; Bronstein MD; Brue T; Coculescu M; Fleseriu M; Guitelman M; Pronin V; Raverot G; Shimon I; Lievre KK; Fleck J; Aout M; Pedroncelli AM; Colao A;
Lancet Diabetes Endocrinol; 2014 Nov; 2(11):875-84. PubMed ID: 25260838
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly.
Colao A; Marzullo P; Ferone D; Marinò V; Pivonello R; Di Somma C; Di Sarno A; Giaccio A; Lombardi G
J Endocrinol Invest; 1999 Jan; 22(1):40-7. PubMed ID: 10090136
[TBL] [Abstract][Full Text] [Related]
15. Cardiac and metabolic effects of chronic growth hormone and insulin-like growth factor I excess in young adults with pituitary gigantism.
Bondanelli M; Bonadonna S; Ambrosio MR; Doga M; Gola M; Onofri A; Zatelli MC; Giustina A; degli Uberti EC
Metabolism; 2005 Sep; 54(9):1174-80. PubMed ID: 16125529
[TBL] [Abstract][Full Text] [Related]
16. Effects of 1-year treatment with octreotide on cardiac performance in patients with acromegaly.
Colao A; Cuocolo A; Marzullo P; Nicolai E; Ferone D; Florimonte L; Salvatore M; Lombardi G
J Clin Endocrinol Metab; 1999 Jan; 84(1):17-23. PubMed ID: 9920056
[TBL] [Abstract][Full Text] [Related]
17. Cardiovascular effects of depot long-acting somatostatin analog Sandostatin LAR in acromegaly.
Colao A; Marzullo P; Ferone D; Spinelli L; Cuocolo A; Bonaduce D; Salvatore M; Boerlin V; Lancranjan I; Lombardi G
J Clin Endocrinol Metab; 2000 Sep; 85(9):3132-40. PubMed ID: 10999798
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of the new long-acting formulation of lanreotide (lanreotide Autogel) in the management of acromegaly.
Caron P; Beckers A; Cullen DR; Goth MI; Gutt B; Laurberg P; Pico AM; Valimaki M; Zgliczynski W
J Clin Endocrinol Metab; 2002 Jan; 87(1):99-104. PubMed ID: 11788630
[TBL] [Abstract][Full Text] [Related]
19. Three year follow-up of acromegalic patients treated with intramuscular slow-release lanreotide.
Caron P; Morange-Ramos I; Cogne M; Jaquet P
J Clin Endocrinol Metab; 1997 Jan; 82(1):18-22. PubMed ID: 8989225
[TBL] [Abstract][Full Text] [Related]
20. Long-term treatment of acromegaly with the somatostatin analogue SR-lanreotide.
Suliman M; Jenkins R; Ross R; Powell T; Battersby R; Cullen DR
J Endocrinol Invest; 1999 Jun; 22(6):409-18. PubMed ID: 10435849
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
